State Board of Administration of Florida Retirement System cut its stake in shares of DexCom, Inc. (NASDAQ:DXCM) by 2.4% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The fund owned 117,881 shares of the medical device company’s stock after selling 2,866 shares during the period. State Board of Administration of Florida Retirement System owned 0.13% of DexCom worth $16,862,000 as of its most recent filing with the SEC.

A number of other hedge funds and other institutional investors also recently modified their holdings of the stock. Zurcher Kantonalbank Zurich Cantonalbank boosted its position in DexCom by 9.3% during the second quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 5,552 shares of the medical device company’s stock valued at $527,000 after purchasing an additional 471 shares during the last quarter. Metropolitan Life Insurance Co. NY boosted its position in DexCom by 7.6% during the second quarter. Metropolitan Life Insurance Co. NY now owns 6,879 shares of the medical device company’s stock valued at $653,000 after purchasing an additional 486 shares during the last quarter. Xact Kapitalforvaltning AB boosted its position in DexCom by 4.1% during the second quarter. Xact Kapitalforvaltning AB now owns 12,700 shares of the medical device company’s stock valued at $1,206,000 after purchasing an additional 500 shares during the last quarter. Oppenheimer & Co. Inc. lifted its position in shares of DexCom by 23.8% in the third quarter. Oppenheimer & Co. Inc. now owns 3,282 shares of the medical device company’s stock valued at $469,000 after buying an additional 630 shares during the last quarter. Finally, Creative Planning lifted its position in shares of DexCom by 6.7% in the third quarter. Creative Planning now owns 10,466 shares of the medical device company’s stock valued at $1,497,000 after buying an additional 659 shares during the last quarter.

A number of analysts have recently issued reports on DXCM shares. Northland Securities raised DexCom from an “under perform” rating to a “market perform” rating in a research report on Wednesday, September 12th. Stephens raised their price objective on DexCom from $135.00 to $160.00 and gave the company an “overweight” rating in a research report on Thursday, August 23rd. Canaccord Genuity raised their price objective on DexCom from $125.00 to $150.00 and gave the company a “buy” rating in a research report on Thursday, August 23rd. Piper Jaffray Companies raised their price objective on DexCom to $150.00 and gave the company an “overweight” rating in a research report on Thursday, August 2nd. Finally, BidaskClub raised DexCom from a “buy” rating to a “strong-buy” rating in a research report on Tuesday, August 21st. Seven equities research analysts have rated the stock with a hold rating, fourteen have issued a buy rating and one has issued a strong buy rating to the company. The company presently has a consensus rating of “Buy” and an average target price of $132.50.

NASDAQ:DXCM opened at $149.46 on Friday. The company has a market cap of $12.85 billion, a P/E ratio of -257.69 and a beta of 0.60. The company has a quick ratio of 4.62, a current ratio of 4.71 and a debt-to-equity ratio of 0.60. DexCom, Inc. has a 1-year low of $49.80 and a 1-year high of $152.14.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Tuesday, November 6th. The medical device company reported $0.17 earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.12) by $0.29. The business had revenue of $266.70 million during the quarter, compared to analysts’ expectations of $242.72 million. DexCom had a negative return on equity of 2.89% and a net margin of 4.72%. The firm’s revenue was up 44.5% on a year-over-year basis. As a group, equities research analysts forecast that DexCom, Inc. will post -0.22 earnings per share for the current year.

In related news, EVP Steven Robert Pacelli sold 3,114 shares of DexCom stock in a transaction that occurred on Thursday, August 23rd. The stock was sold at an average price of $139.96, for a total transaction of $435,835.44. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Kevin R. Sayer sold 11,161 shares of DexCom stock in a transaction that occurred on Monday, August 13th. The stock was sold at an average price of $123.22, for a total value of $1,375,258.42. The disclosure for this sale can be found here. Over the last three months, insiders have sold 157,892 shares of company stock valued at $21,864,030. 1.80% of the stock is currently owned by insiders.

COPYRIGHT VIOLATION WARNING: This article was first posted by Daily Political and is owned by of Daily Political. If you are accessing this article on another publication, it was illegally stolen and reposted in violation of U.S. and international trademark and copyright laws. The correct version of this article can be viewed at https://www.dailypolitical.com/2018/11/10/state-board-of-administration-of-florida-retirement-system-sells-2866-shares-of-dexcom-inc-dxcm.html.

About DexCom

DexCom, Inc, a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for ambulatory use by people with diabetes; and for use by healthcare providers. Its products include DexCom G5 mobile continuous glucose monitoring system to communicate directly to patient's mobile device; DexCom G4 PLATINUM system for continuous use by adults with diabetes; and DexCom Share, a remote monitoring system.

Recommended Story: How to Calculate Compound Annual Growth Rate (CAGR)

Want to see what other hedge funds are holding DXCM? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for DexCom, Inc. (NASDAQ:DXCM).

Institutional Ownership by Quarter for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.